Whitehawk Therapeutics (WHWK) Non-Current Assets (2016 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Non-Current Assets of $1.7 million for Q1 2026, up 21.25% year-over-year from $1.4 million in Q1 2025, and down 7.37% quarter-over-quarter from $1.8 million in Q4 2025.
Whitehawk Therapeutics (WHWK) Non-Current Assets (2016 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Non-Current Assets for 11 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 21.25% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $7.6 million (down 72.16% YoY), while the FY2025 annual figure was $1.8 million, down 79.88% from the prior year.
- Non-Current Assets slipped to $1.7 million in Q1 2026 per WHWK's latest filing, from $1.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $9.0 million in Q4 2024 and bottomed at $1.4 million in Q1 2025.
- Historically, Non-Current Assets has averaged $5.3 million across 5 years, with a median of $5.7 million in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 14503.42% — and 2025, when it plunged 83.67%.
- Whitehawk Therapeutics' Non-Current Assets stood at $4.2 million in 2022, then surged by 86.24% to $7.8 million in 2023, then climbed by 15.25% to $9.0 million in 2024, then tumbled by 79.88% to $1.8 million in 2025, then slipped by 7.37% to $1.7 million in 2026.
- Business Quant data shows WHWK's Non-Current Assets at $1.7 million in Q1 2026, $1.8 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | 1.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Mn |
| Mar 31, 2026 | 1.68 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 2.15 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 9.03 Mn |
| Sep 30, 2024 | 8.38 Mn |
| Jun 30, 2024 | 8.62 Mn |
| Mar 31, 2024 | 8.50 Mn |
| Dec 31, 2023 | 7.84 Mn |
| Sep 30, 2023 | 6.78 Mn |
| Jun 30, 2023 | 6.31 Mn |
| Mar 31, 2023 | 5.72 Mn |
| Dec 31, 2022 | 4.21 Mn |
| Sep 30, 2022 | 4.24 Mn |
| Jun 30, 2022 | 4.30 Mn |
| Mar 31, 2022 | 6.70 Mn |
| Dec 31, 2021 | 6.64 Mn |
| Sep 30, 2021 | 6.75 Mn |